Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2011

01.01.2011 | Guidelines

EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting

verfasst von: M. Lassmann, C. Chiesa, G. Flux, M. Bardiès

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Many recent publications in nuclear medicine contain data on dosimetric findings for existing and new diagnostic and therapeutic agents. In many of these articles, however, a description of the methodology applied for dosimetry is lacking or important details are omitted. The intention of the EANM Dosimetry Committee is to guide the reader through a series of suggestions for reporting dosimetric approaches. The authors are aware of the large amount of data required to report the way a given clinical dosimetry procedure was implemented. Another aim of this guidance document is to provide comprehensive information for preparing and submitting publications and reports containing data on internal dosimetry. This guidance document also contains a checklist which could be useful for reviewers of manuscripts submitted to scientific journals or for grant applications. In addition, this document could be used to decide which data are useful for a documentation of dosimetry results in individual patient records. This may be of importance when the approval of a new radiopharmaceutical by official bodies such as EMA or FDA is envisaged.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
In some journals it is also possible to submit additional material that also offers an opportunity to keep the manuscript short but provides enough detail for a proper evaluation of the methodology and the results.
 
2
Traditionally called “MIRD scheme“ or “MIRD method“
 
Literatur
1.
Zurück zum Zitat Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005;46 Suppl 1:128S–40S.PubMed Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005;46 Suppl 1:128S–40S.PubMed
2.
Zurück zum Zitat Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195–9.CrossRefPubMed Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195–9.CrossRefPubMed
3.
4.
Zurück zum Zitat Busemann Sokole E, Plachcinska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010;37:662–71.CrossRefPubMed Busemann Sokole E, Plachcinska A, Britten A, Lyra Georgosopoulou M, Tindale W, Klett R. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010;37:662–71.CrossRefPubMed
5.
Zurück zum Zitat Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;45:619–25.PubMed Lassmann M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;45:619–25.PubMed
6.
Zurück zum Zitat Jonsson L, Ljungberg M, Strand SE. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med 2005;46:1679–86.PubMed Jonsson L, Ljungberg M, Strand SE. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med 2005;46:1679–86.PubMed
7.
Zurück zum Zitat He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, et al. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys 2009;36:612–9.CrossRefPubMed He B, Du Y, Segars WP, Wahl RL, Sgouros G, Jacene H, et al. Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys 2009;36:612–9.CrossRefPubMed
8.
Zurück zum Zitat Assié K, Dieudonne A, Gardin I, Buvat I, Tilly H, Vera P. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2008;23:53–64.CrossRefPubMed Assié K, Dieudonne A, Gardin I, Buvat I, Tilly H, Vera P. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2008;23:53–64.CrossRefPubMed
9.
Zurück zum Zitat Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 2010;37:1408–25.CrossRefPubMed Vriens D, Visser EP, de Geus-Oei LF, Oyen WJ. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging 2010;37:1408–25.CrossRefPubMed
10.
Zurück zum Zitat Jaszczak RJ, Floyd CE, Coleman RE. Scatter compensation techniques for SPECT. IEEE Trans Nucl Sci 1985;32:786–93.CrossRef Jaszczak RJ, Floyd CE, Coleman RE. Scatter compensation techniques for SPECT. IEEE Trans Nucl Sci 1985;32:786–93.CrossRef
11.
Zurück zum Zitat Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med 1993;34:2216–21.PubMed Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med 1993;34:2216–21.PubMed
12.
Zurück zum Zitat Jentzen W. Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol. 2010;55:2365–98.CrossRefPubMed Jentzen W. Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging. Phys Med Biol. 2010;55:2365–98.CrossRefPubMed
13.
Zurück zum Zitat Jentzen W, Weise R, Kupferschlager J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008;35:611–23.CrossRefPubMed Jentzen W, Weise R, Kupferschlager J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008;35:611–23.CrossRefPubMed
14.
Zurück zum Zitat Hobbs RF, Baechler S, van Senthamizhchel S, Prideaux AR, Esaias CE, Reinhardt M, et al. A gamma camera count rate saturation correction method for whole-body planar imaging. Phys Med Biol 2010;55:817–31.CrossRefPubMed Hobbs RF, Baechler S, van Senthamizhchel S, Prideaux AR, Esaias CE, Reinhardt M, et al. A gamma camera count rate saturation correction method for whole-body planar imaging. Phys Med Biol 2010;55:817–31.CrossRefPubMed
15.
Zurück zum Zitat Chiesa C, Negri A, Albertini C, Azzeroni R, Setti E, Mainardi L, et al. (2009) A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy. Q J Nucl Med Mol Imaging 2009;53:658–70PubMed Chiesa C, Negri A, Albertini C, Azzeroni R, Setti E, Mainardi L, et al. (2009) A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy. Q J Nucl Med Mol Imaging 2009;53:658–70PubMed
16.
Zurück zum Zitat Gregory RA, Hooker CA, Partridge M, Flux GD. Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system. Eur J Nucl Med Mol Imaging 2009;36:1037–48.CrossRefPubMed Gregory RA, Hooker CA, Partridge M, Flux GD. Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system. Eur J Nucl Med Mol Imaging 2009;36:1037–48.CrossRefPubMed
17.
Zurück zum Zitat Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354–61.CrossRefPubMed Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354–61.CrossRefPubMed
18.
Zurück zum Zitat Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405–12.CrossRefPubMed Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405–12.CrossRefPubMed
19.
Zurück zum Zitat Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47:3211–23.CrossRefPubMed Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol 2002;47:3211–23.CrossRefPubMed
20.
Zurück zum Zitat Divoli A, Spinelli A, Chittenden S, Dearnaley D, Flux G. Whole-body dosimetry for targeted radionuclide therapy using spectral analysis. Cancer Biother Radiopharm 2005;20:66–71.CrossRefPubMed Divoli A, Spinelli A, Chittenden S, Dearnaley D, Flux G. Whole-body dosimetry for targeted radionuclide therapy using spectral analysis. Cancer Biother Radiopharm 2005;20:66–71.CrossRefPubMed
21.
Zurück zum Zitat Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 2007;34:4285–92.CrossRefPubMed Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 2007;34:4285–92.CrossRefPubMed
22.
Zurück zum Zitat Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry – standardization of nomenclature. J Nucl Med 2009;50:477–84.CrossRefPubMed Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry – standardization of nomenclature. J Nucl Med 2009;50:477–84.CrossRefPubMed
23.
Zurück zum Zitat Divoli A, Chiavassa S, Ferrer L, Barbet J, Flux GD, Bardies M. Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies. J Nucl Med 2009;50:316–23.CrossRefPubMed Divoli A, Chiavassa S, Ferrer L, Barbet J, Flux GD, Bardies M. Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies. J Nucl Med 2009;50:316–23.CrossRefPubMed
24.
Zurück zum Zitat International Commission on Radiation Units. Absorbed-dose specifications in nuclear medicine. J ICRU. 2002;2:5–110. International Commission on Radiation Units. Absorbed-dose specifications in nuclear medicine. J ICRU. 2002;2:5–110.
25.
Zurück zum Zitat Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed
26.
Zurück zum Zitat Grosev D, Loncaric S, Huic D, Dodig D. Geometric models in dosimetry of thyroid remnant mass. Nuklearmedizin 2008;47:120–6.PubMed Grosev D, Loncaric S, Huic D, Dodig D. Geometric models in dosimetry of thyroid remnant mass. Nuklearmedizin 2008;47:120–6.PubMed
27.
28.
Zurück zum Zitat O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40:1337–41.PubMed O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40:1337–41.PubMed
Metadaten
Titel
EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting
verfasst von
M. Lassmann
C. Chiesa
G. Flux
M. Bardiès
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1549-3

Weitere Artikel der Ausgabe 1/2011

European Journal of Nuclear Medicine and Molecular Imaging 1/2011 Zur Ausgabe